Business Overview
Natera (NTRA US) is a market-leading molecular diagnostics company which has developed best-in-class technology for utilizing cell-free DNA (cfDNA) in diagnostic applications, including Women’s Health, Oncology, and Organ Transplant. The platform linking these various applications is an expertise in molecular biology and bioinformatic algorithms that allow NTRA to identify biomarkers (cfDNA fragments linked to various disease states) and to leverage data science that leads to tests which accurately link the presence of those biomarkers to a disease state. NTRA perfected this platform in its core Women’s Health business, which represents ~80% of revenue and operates in a well-established market with a TAM of ~$5B. NTRA has subsequently leveraged this expertise to create products in Oncology and Organ Transplant.